| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRD2411 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/nrd2411 |
| P698 | PubMed publication ID | 18049473 |
| P5875 | ResearchGate publication ID | 5799431 |
| P50 | author | Michael Manns | Q1564831 |
| Stefan Zeuzem | Q28360321 | ||
| Jürgen Rockstroh | Q47006499 | ||
| P2093 | author name string | Fabien Zoulim | |
| Graham R Foster | |||
| Michael Houghton | |||
| P2860 | cites work | AIDS — The First 20 Years | Q22250904 |
| Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378] | Q24805127 | ||
| Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro | Q27472610 | ||
| Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus | Q27473236 | ||
| In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor | Q27473320 | ||
| NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon | Q27477455 | ||
| Novel Alpha Interferon (IFN- ) Variant with Improved Inhibitory Activity against Hepatitis C Virus Genotype 1 Replication Compared to IFN- 2b Therapy in a Subgenomic Replicon System | Q27477758 | ||
| Small Interfering RNA Targeted to Hepatitis C Virus 5' Nontranslated Region Exerts Potent Antiviral Effect | Q27478036 | ||
| Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution | Q27486234 | ||
| Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome | Q27860719 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group | Q27861083 | ||
| Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients | Q28274666 | ||
| Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial | Q28298301 | ||
| An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus | Q29614207 | ||
| Unravelling hepatitis C virus replication from genome to function | Q29620056 | ||
| Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models | Q33867634 | ||
| Epidemiology of hepatitis C virus (HCV) infection | Q33995067 | ||
| Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites | Q34323105 | ||
| Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. | Q34364260 | ||
| Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease | Q34540250 | ||
| Barriers to the treatment of hepatitis C. Patient, provider, and system factors | Q34723678 | ||
| Hepatitis C therapeutics: current status and emerging strategies | Q34988230 | ||
| The nature of interferon-alpha resistance in hepatitis C virus infection | Q35587136 | ||
| Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. | Q35651729 | ||
| Hepatocellular carcinoma: recent trends in Japan. | Q35929168 | ||
| The hepatitis C virus replicon system: from basic research to clinical application | Q36167309 | ||
| Challenges and successes in developing new therapies for hepatitis C. | Q36233823 | ||
| Prospects for a vaccine against the hepatitis C virus | Q36233831 | ||
| HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase | Q36244361 | ||
| The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice | Q36346615 | ||
| American Gastroenterological Association technical review on the management of hepatitis C. | Q36364156 | ||
| The culture of designing hepato-biliary randomised trials | Q36376599 | ||
| Management of patients with chronic hepatitis C infection | Q36426884 | ||
| Nucleoside analog inhibitors of hepatitis C virus replication | Q36513114 | ||
| Treating viral hepatitis C: efficacy, side effects, and complications | Q36564615 | ||
| Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors | Q40156293 | ||
| Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro | Q40237403 | ||
| In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance | Q40277481 | ||
| Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. | Q40322833 | ||
| Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. | Q40344643 | ||
| Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons | Q40352710 | ||
| Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells | Q40425026 | ||
| Comparing the public health burden of chronic hepatitis C and HIV infection in France | Q40536251 | ||
| A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. | Q40547706 | ||
| Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro | Q40550747 | ||
| Projecting future complications of chronic hepatitis C in the United States | Q40594872 | ||
| Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro | Q40882812 | ||
| Treatment of chronic HCV infection in special populations | Q41832622 | ||
| Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial | Q41839327 | ||
| In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms | Q42982898 | ||
| Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. | Q42990950 | ||
| Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. | Q42991459 | ||
| In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. | Q42994273 | ||
| A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients | Q42996491 | ||
| A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees | Q42998134 | ||
| Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. | Q42999156 | ||
| Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*. | Q42999426 | ||
| Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens. | Q42999430 | ||
| Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin | Q42999474 | ||
| Peginterferon alfa-2a in patients with chronic hepatitis C. | Q43001243 | ||
| Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. | Q43001787 | ||
| Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine | Q43029925 | ||
| Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study | Q43032179 | ||
| A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. | Q43033369 | ||
| SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders | Q43036959 | ||
| Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir | Q43037585 | ||
| A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group | Q43039883 | ||
| Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus | Q43041294 | ||
| Peginterferon alpha/ribavirin combination therapy for the treatment of hepatitis C infection | Q43895274 | ||
| Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment | Q44901526 | ||
| Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I | Q45752944 | ||
| Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial | Q46790729 | ||
| Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. | Q46873874 | ||
| Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. | Q49168520 | ||
| Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. | Q50579007 | ||
| Structural biology of hepatitis C virus | Q56762917 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 991-1000 | |
| P577 | publication date | 2007-12-01 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | The way forward in HCV treatment--finding the right path | |
| P478 | volume | 6 |
| Q27487390 | 1,5-Benzodiazepines, a Novel Class of Hepatitis C Virus Polymerase Nonnucleoside Inhibitors |
| Q42924747 | 7-O-Arylmethylgalangin as a novel scaffold for anti-HCV agents |
| Q39374800 | A 2'-deoxy-2'-fluoro-2'-C-methyl uridine cyclopentyl carbocyclic analog and its phosphoramidate prodrug as inhibitors of HCV NS5B polymerase |
| Q27490546 | A Novel Class of meso-Tetrakis-Porphyrin Derivatives Exhibits Potent Activities against Hepatitis C Virus Genotype 1b Replicons In Vitro |
| Q34427768 | A cell culture adapted HCV JFH1 variant that increases viral titers and permits the production of high titer infectious chimeric reporter viruses |
| Q37862076 | A new standard of care for the treatment of chronic HCV infection |
| Q37540618 | A small molecule inhibits HCV replication and alters NS4B's subcellular distribution. |
| Q37608313 | A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges. |
| Q83578903 | Advanced chronic hepatitis C: how to handle if you cannot halt? |
| Q37805992 | Advances in nucleoside monophosphate prodrugs as anti-HCV agents |
| Q27490799 | An antioxidant resveratrol significantly enhanced replication of hepatitis C virus |
| Q42694877 | Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin |
| Q56786267 | Anti-DNA Virus Agents |
| Q42979304 | Anti-hepatitis C virus activity of 3-hydroxy caruilignan C from Swietenia macrophylla stems |
| Q35139538 | Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase |
| Q27488713 | Antiviral effect of interferon lambda against West Nile virus |
| Q51721067 | Antiviral therapy: quo vadis? |
| Q37195548 | Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma |
| Q56786312 | Antivirals: current state of the art |
| Q42215059 | Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C. |
| Q37611819 | CD81 and hepatitis C virus (HCV) infection. |
| Q41118833 | Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans |
| Q34022149 | Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect |
| Q26998630 | Chutes and ladders in hepatitis C nucleoside drug development |
| Q28535361 | Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics |
| Q39782699 | Cost-effectiveness of targeted screening for hepatitis C in The Netherlands |
| Q35887719 | Current status and future directions in the management of chronic hepatitis C. |
| Q37519635 | DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target. |
| Q24645702 | Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors |
| Q37274697 | Design of therapeutic vaccines: hepatitis B as an example |
| Q38122005 | Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection |
| Q41201956 | Direct-acting antiviral treatment of chronic hepatitis C infection |
| Q28550311 | Drug Pricing Evolution in Hepatitis C |
| Q56786308 | Emerging antiviral drugs |
| Q35013989 | Emerging therapies for chronic hepatitis C virus |
| Q37772514 | Emerging therapies for hepatitis C virus |
| Q39917960 | Evaluation of a hepatitis B vaccination program in Taiwan: impact on hepatocellular carcinoma development |
| Q27488854 | HCV antibody response and genotype distribution in different areas and races of China |
| Q37664059 | HCV drug discovery aimed at viral eradication |
| Q34957256 | Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy |
| Q37835699 | Hepatitis in 2010: the dawn of a new era in HCV therapy |
| Q51825330 | Hot topics in HIV and hepatitis coinfection: noninvasive diagnosis of liver disease, liver transplantation, and new drugs for treatment of hepatitis coinfection. |
| Q38071388 | How to optimize HCV therapy in genotype 4 patients. |
| Q37271640 | Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus |
| Q39718332 | Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B. |
| Q34510773 | Identification of hidden key hepatitis C populations: an evaluation of screening practices using mixed epidemiological methods |
| Q37970381 | Immunosuppression, liver injury and post-transplant HCV recurrence |
| Q30371832 | Immunotherapy for HCV infection: next steps. |
| Q27491011 | Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway |
| Q24650264 | In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor |
| Q39736457 | In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. |
| Q39479021 | Inhibition of hepatitis C virus replication through adenosine monophosphate-activated protein kinase-dependent and -independent pathways |
| Q27660398 | Inhibitor-induced structural change in the HCV IRES domain IIa RNA |
| Q39617748 | Inhibitors of endoplasmic reticulum alpha-glucosidases potently suppress hepatitis C virus virion assembly and release |
| Q33452082 | Insight into ligand selectivity in HCV NS5B polymerase: molecular dynamics simulations, free energy decomposition and docking |
| Q39163980 | Instrumental support to facilitate hepatitis C treatment adherence: working around shortfalls in shared-care |
| Q37288393 | Interferon-based therapy for chronic hepatitis C: current and future perspectives |
| Q33991988 | Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone. |
| Q36117549 | Investigation of the Immunomodulatory effect of Berberis vulgaris on core-pulsed dendritic cell vaccine |
| Q41255502 | LC-ESI-MS/MS analysis and pharmacokinetics of GP205, an innovative potent macrocyclic inhibitor of hepatitis C virus NS3/4A protease in rats |
| Q50046328 | Lignans, flavonoids and coumarins from Viola philippica and their α-glucosidase and HCV protease inhibitory activities. |
| Q43288824 | Looking back in 2009 at the dawning of antiviral therapy now 50 years ago an historical perspective |
| Q27490545 | MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease |
| Q42246358 | Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155K, D168A and A156V). |
| Q28479129 | Mortality among patients with cleared hepatitis C virus infection compared to the general population: a Danish nationwide cohort study |
| Q35399890 | Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. |
| Q45879913 | New approaches to the management of hepatitis C in haemophilia in 2012. |
| Q38842758 | New combination antiviral for the treatment of hepatitis C. |
| Q35653358 | New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy |
| Q35833006 | New treatments for chronic hepatitis C. |
| Q39452230 | Non-genotype-specific role of the hepatitis C virus 5' untranslated region in virus production and in inhibition by interferon |
| Q39167685 | Norovirus infection in primary immune deficiency |
| Q39200275 | Novel anilinocoumarin derivatives as agents against hepatitis C virus by the induction of IFN-mediated antiviral responses |
| Q34206832 | Novel approaches to flavivirus drug discovery |
| Q35828072 | Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb. |
| Q37855863 | Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends |
| Q27490760 | On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula |
| Q27656967 | Optimization of thienopyrrole-based finger-loop inhibitors of the hepatitis C virus NS5B polymerase |
| Q56786253 | Outlook of the Antiviral Drug Era, Now More Than 50 Years after Description of the First Antiviral Drug |
| Q37818336 | Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients |
| Q37972757 | Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1. |
| Q36558549 | Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase |
| Q39579921 | Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family |
| Q28480947 | Probing of exosites leads to novel inhibitor scaffolds of HCV NS3/4A proteinase |
| Q27486984 | RETRACTED: Selection of cyclic peptide aptamers to HCV IRES RNA using mRNA display |
| Q34551913 | Rapid emergence of protease inhibitor resistance in hepatitis C virus |
| Q35666596 | Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor |
| Q36558519 | Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems |
| Q37358620 | Scotomas in molecular virology and epidemiology of hepatitis C virus |
| Q37503337 | Serine protease inhibitors as anti-hepatitis C virus agents |
| Q35867385 | Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. |
| Q23011530 | Structure and functionality in flavivirus NS-proteins: perspectives for drug design |
| Q39329242 | TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage |
| Q38615654 | Targeting HCV entry for development of therapeutics |
| Q37820902 | The Future of HCV Therapy: NS4B as an Antiviral Target |
| Q37790484 | The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C. |
| Q42981071 | The discovery of pyrano[3,4-b]indole-based allosteric inhibitors of HCV NS5B polymerase with in vivo activity |
| Q37972775 | The future for the treatment of genotype 4 chronic hepatitis C. |
| Q39554467 | The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein |
| Q50562489 | Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. |
| Q38581478 | Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. |
| Q35714749 | Treatment of HCV patients before and after renal transplantation |
| Q33899320 | Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling |
| Q83835992 | [Viral hepatitis B und C] |
Search more.